Clinical Trial

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Name: Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation — clinical trial record (NCT06015568)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To evaluate the safety and tolerance of MCLA-129 combined with Befotertinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations.

Trial Details

NCT Number	NCT06015568
Lead Sponsor	Betta Pharmaceuticals Co., Ltd.
Conditions	Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Enrollment	172 participants
Start Date	2023-09-01
Primary Completion	2028-11-04 (estimated)
Study Completion	2029-07-04 (estimated)
Updated on ClinicalTrials.gov	2023-08-29